Sarepta Therapeutics Inc Stock Price, News & Analysis

Sarepta Therapeutics announced top-line results for Study SRP-9001-102, assessing the investigational gene therapy SRP-9001 in patients with Duchenne muscular dystrophy. The study met its primary biological endpoint, showing a 28.1% mean micro-dystrophin protein expression at 12 weeks. However, it failed to achieve statistical significance on the primary functional endpoint of the NSAA total score at 48 weeks. Notably, participants aged 4-5 showed a significant improvement of 4.3 points in NSAA compared to placebo. No new safety signals were identified, supporting SRP-9001's favorable safety profile.

Sarepta Therapeutics (NASDAQ:SRPT) announced the granting of equity awards to 11 new employees as part of its 2014 Employment Commencement Incentive Plan, approved by its Compensation Committee. A total of options for 4,525 shares and 1,720 restricted stock units (RSUs) were awarded, with options priced at $170.49 per share, reflecting the stock's closing price on the grant date (Dec 31, 2020). The options and RSUs will vest over a four-year period, contingent on continued employment. This move aims to attract talent in the field of precision genetic medicine.

Sarepta Therapeutics has announced key executive appointments, including Ian Estepan as chief financial officer, Dallan Murray as chief commercial officer, and Louise Rodino-Klapac, Ph.D., as chief scientific officer. These changes aim to strengthen the leadership team and enhance operational efficiency. Ty Howton will retire as general counsel, with Ryan Brown stepping in as interim general counsel. Estepan's previous experience in corporate strategy and capital acquisition, along with Murray's commercial expertise, positions them to drive Sarepta's growth in genetic medicine.

Sarepta Therapeutics (NASDAQ:SRPT) announced promising results from its Phase 2 MOMENTUM study (Study 5051-201) for SRP-5051, a treatment for Duchenne muscular dystrophy (DMD) aimed at exon 51 skipping. The trial showed that a dose of 20 mg/kg led to significantly improved tissue exposure, exon skipping, and dystrophin production, with results noted after just 12 weeks. SRP-5051 was well-tolerated across all doses, supporting continued clinical development. Comparatively, SRP-5051 demonstrated superior efficacy over eteplirsen with a lower dose exposure, making it a potential game-changer in DMD treatment.

Sarepta Therapeutics (NASDAQ:SRPT) will host a webcast on Dec. 7, 2020, at 8:30 AM ET, to present interim data from the MOMENTUM study, focusing on SRP-5051 for Duchenne muscular dystrophy treatment. SRP-5051 is the first investigational treatment utilizing Sarepta's next-generation PPMO platform, aiming to enhance drug concentration in muscle tissue. The webcast will be available on their investor relations website, with a call accessible via specific dialing instructions provided in the release.

Sarepta Therapeutics (NASDAQ:SRPT) announced the granting of equity awards to 28 newly hired employees on November 30, 2020, as part of its 2014 Employment Commencement Incentive Plan. These awards include options to purchase 35,770 shares and 15,000 restricted stock units (RSUs). The options have an exercise price of $140.86 per share, equivalent to the stock's closing price on the grant date. Both options and RSUs will vest over four years, contingent on continued employment with the company.

Sarepta Therapeutics (NASDAQ:SRPT) announced its participation in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 2, 2020, at 3:30 p.m. E.T. The event will be available via a live webcast on Sarepta's website and archived for 90 days. Sarepta is recognized for its innovations in precision genetic medicine for rare diseases, particularly in Duchenne muscular dystrophy (DMD), with over 40 programs underway across various therapeutic modalities including RNA and gene therapy.

Sarepta Therapeutics (NASDAQ:SRPT) has been recognized by The Boston Globe as one of the Top Places to Work in 2020 in the large company category. This ranking is based on employee surveys addressing company direction, management, and work benefits. CEO Doug Ingram highlighted the dedication of employees in maintaining a positive culture during a challenging year. The company continues to innovate in precision genetic medicine and has implemented several initiatives to support employees through the pandemic, including caregiving benefits and virtual wellness seminars.

Sarepta Therapeutics (NASDAQ:SRPT) reported a 23% increase in third-quarter 2020 net product sales, totaling $121.4 million, compared to $99.0 million in Q3 2019. Despite challenges from the pandemic, the company advanced its pipeline, with FDA acceptance of the NDA for casimersen and positive data from gene therapy trials, including SRP-9001 and SRP-9003. However, Sarepta reported a net loss of $196.5 million for the quarter. The company's cash reserves increased to $1.8 billion due to strategic financing activities.